Akebia Therapeutics, Inc.
Akebia Therapeutics, Inc. (AKBA) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · AKBA · as of Sep 30, 2025
Ownership Breakdown
183
Institutional Holders
▲ 20 vs Q2
$337.74M
Total Inst. Value
▼ $56.45M vs Q2
268.26M
Shares Outstanding
freeFloat 97.78%
123.69M
13F Shares Held
▲ 15.40M vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
AKBA largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
BLACKROCK, INC. pharmaceutical preparations | 18.80M | 7.16% | 7.16% | $51.32B | Nov 12, 2025 | ▲ 423.1K |
VANGUARD GROUP INC pharmaceutical preparations | 15.55M | 5.92% | 5.92% | $42.44B | Nov 7, 2025 | ▲ 936.0K |
STATE STREET CORP pharmaceutical preparations | 11.84M | 4.51% | 4.51% | $32.34B | Nov 14, 2025 | ▲ 3.85M |
GEODE CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 6.18M | 2.36% | 2.36% | $16.89B | Nov 12, 2025 | ▲ 110.5K |
MORGAN STANLEY pharmaceutical preparations | 4.32M | 1.64% | 1.64% | $11.78B | May 27, 2026 | ▼ 1.02M |
RENAISSANCE TECHNOLOGIES LLC pharmaceutical preparations | 3.95M | 1.51% | 1.51% | $10.79B | Nov 13, 2025 | ▼ 241.7K |
UBS GROUP AG pharmaceutical preparations | 3.65M | 1.39% | 1.39% | $9.95B | Nov 13, 2025 | ▲ 3.01M |
QUBE RESEARCH & TECHNOLOGIES LTD pharmaceutical preparations | 3.21M | 1.22% | 1.22% | $8.75B | Nov 14, 2025 | ▲ 1.49M |
CITADEL ADVISORS LLC pharmaceutical preparations | 3.19M | 1.21% | 1.21% | $8.70B | Nov 14, 2025 | ▲ 868.5K |
BIOIMPACT CAPITAL LLC pharmaceutical preparations | 2.89M | 1.10% | 1.10% | $7.89B | Nov 14, 2025 | — held |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
33
Increased
+23.32M shares3
New Positions
first time holders11
Decreased
−5.64M shares0
Sold Out
fully exitedNet shares change (top 50)
+17.68M
+23.32M / −5.64M
Net new holders
+25
3 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
AKBA insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
1
Buy transactions
0
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Vickers Philip J. director | Apr 1, 2026 | Award | 214,400 | $1.41 | $302.3K | 214.4K | Form 4 ↗ |
Butler John P. CEO and President | Mar 4, 2026 | Purchase | 69,270 | $1.25 | $86.6K | 3.37M | Form 4 ↗ |
Malabre Richard C SVP, Chief Accounting Officer | Feb 2, 2026 | Sale | 36,142 | $1.39 | $50.2K | 312.8K | Form 4 ↗ |
Malabre Richard C SVP, Chief Accounting Officer | Feb 2, 2026 | Sale | 13,382 | $1.39 | $18.6K | 299.4K | Form 4 ↗ |
Grund Nicholas Chief Commercial Officer | Feb 2, 2026 | Sale | 53,585 | $1.39 | $74.5K | 593.0K | Form 4 ↗ |
Grund Nicholas Chief Commercial Officer | Feb 2, 2026 | Sale | 31,244 | $1.39 | $43.4K | 561.8K | Form 4 ↗ |
Burke Steven Keith SVP, Chief Medical Officer | Feb 2, 2026 | Sale | 21,582 | $1.39 | $30.0K | 994.5K | Form 4 ↗ |
Burke Steven Keith SVP, Chief Medical Officer | Feb 2, 2026 | Sale | 25,375 | $1.39 | $35.3K | 969.1K | Form 4 ↗ |
Burke Steven Keith SVP, Chief Medical Officer | Feb 2, 2026 | Sale | 20,701 | $1.39 | $28.8K | 948.4K | Form 4 ↗ |
Rucci Carolyn M. SVP, Chief Legal Officer | Feb 2, 2026 | Sale | 16,846 | $1.39 | $23.4K | 641.3K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Akebia Therapeutics, Inc. (AKBA) is primarily owned by institutional investors, who hold approximately 46.1% of total shares outstanding. Company insiders own approximately 2.22%, while retail and public investors account for the remaining 51.67%.
The largest institutional shareholder of Akebia Therapeutics, Inc. is BLACKROCK, INC., holding approximately 18.80 million shares — equal to 7.16% of outstanding shares — as of September 30, 2025.
A total of 183 institutional investors currently hold AKBA stock, with a combined institutional value of approximately $337,737,603 as of the most recent 13F filing period.
Frequently asked questions
AKBA ownershipAkebia Therapeutics, Inc. (AKBA) is primarily owned by institutional investors, who hold approximately 46.1% of shares. The largest shareholder is BLACKROCK, INC. with a 7.16% stake. Company insiders hold 2.22%. Data sourced from SEC Form 13F as of September 30, 2025.